FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020357816> ?p ?o ?g. }

• W2020357816 endingPage "1674" @default.
• W2020357816 startingPage "1669" @default.
• W2020357816 abstract "Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms of diffuse neuroendocrine cells. Surgery is the main aim in the treatment of NETs, which becomes impossible in the case of large tumours or infiltration into other tissues and/or important blood vessels. Neoadjuvant therapy might be helpful in decreasing NET size also, leading us to the point where a tumour, previously considered inoperable, becomes operable. The aim of the study was to assess the usage of peptide receptor radionuclide therapy (PRRT) as a neoadjuvant treatment, enabling surgical intervention in primary inoperable NET.Among 47 patients treated with PRRT, 6 patients were chosen with large, inoperable tumours, for whom enabling of complete surgical excision of the lesions might offer the prospect for a cure. Response to the therapy was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST).The mean tumour size decreased from 6.9 (min. 3.1 cm, max. 9.6 cm) before therapy to 5.4 cm (min. 3.1 cm, max. 9.5 cm) after the treatment. According to RECIST, stabilization of the disease was observed in four and partial responses in two patients. In two patients, reduction of the tumour size enabled surgical intervention.(1) PRRT might be considered a neoadjuvant therapy in primary inoperable NETs. (2) According to RECIST, stabilization of the disease was observed in the majority of patients. (3) We suggest that not only tumour diameter changes, but also tumour volume and contrast enhancement changes in computed tomography should be taken into consideration in assessment of the response to the therapy. (4) Somatostatin receptor scintigraphy is an important tool for qualification of the radioisotope therapy and also for the assessment of the response to PRRT." @default.
• W2020357816 created "2016-06-24" @default.
• W2020357816 creator A5002155077 @default.
• W2020357816 creator A5005327464 @default.
• W2020357816 creator A5008837385 @default.
• W2020357816 creator A5010530541 @default.
• W2020357816 creator A5025145304 @default.
• W2020357816 creator A5062377015 @default.
• W2020357816 creator A5072474038 @default.
• W2020357816 creator A5073834668 @default.
• W2020357816 creator A5079012181 @default.
• W2020357816 creator A5085576519 @default.
• W2020357816 date "2011-05-11" @default.
• W2020357816 modified "2023-10-10" @default.
• W2020357816 title "Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)" @default.
• W2020357816 cites W1965535343 @default.
• W2020357816 cites W2002962269 @default.
• W2020357816 cites W2006747460 @default.
• W2020357816 cites W2019607817 @default.
• W2020357816 cites W2110922803 @default.
• W2020357816 cites W2123534406 @default.
• W2020357816 cites W2139248078 @default.
• W2020357816 cites W2153935627 @default.
• W2020357816 cites W2164614522 @default.
• W2020357816 cites W2174129640 @default.
• W2020357816 doi "https://doi.org/10.1007/s00259-011-1835-8" @default.
• W2020357816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3151371" @default.
• W2020357816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21559978" @default.
• W2020357816 hasPublicationYear "2011" @default.
• W2020357816 type Work @default.
• W2020357816 sameAs 2020357816 @default.
• W2020357816 citedByCount "85" @default.
• W2020357816 countsByYear W20203578162012 @default.
• W2020357816 countsByYear W20203578162013 @default.
• W2020357816 countsByYear W20203578162014 @default.
• W2020357816 countsByYear W20203578162015 @default.
• W2020357816 countsByYear W20203578162016 @default.
• W2020357816 countsByYear W20203578162017 @default.
• W2020357816 countsByYear W20203578162018 @default.
• W2020357816 countsByYear W20203578162019 @default.
• W2020357816 countsByYear W20203578162020 @default.
• W2020357816 countsByYear W20203578162021 @default.
• W2020357816 countsByYear W20203578162022 @default.
• W2020357816 countsByYear W20203578162023 @default.
• W2020357816 crossrefType "journal-article" @default.
• W2020357816 hasAuthorship W2020357816A5002155077 @default.
• W2020357816 hasAuthorship W2020357816A5005327464 @default.
• W2020357816 hasAuthorship W2020357816A5008837385 @default.
• W2020357816 hasAuthorship W2020357816A5010530541 @default.
• W2020357816 hasAuthorship W2020357816A5025145304 @default.
• W2020357816 hasAuthorship W2020357816A5062377015 @default.
• W2020357816 hasAuthorship W2020357816A5072474038 @default.
• W2020357816 hasAuthorship W2020357816A5073834668 @default.
• W2020357816 hasAuthorship W2020357816A5079012181 @default.
• W2020357816 hasAuthorship W2020357816A5085576519 @default.
• W2020357816 hasBestOaLocation W20203578161 @default.
• W2020357816 hasConcept C121608353 @default.
• W2020357816 hasConcept C126322002 @default.
• W2020357816 hasConcept C126838900 @default.
• W2020357816 hasConcept C143998085 @default.
• W2020357816 hasConcept C170493617 @default.
• W2020357816 hasConcept C203092338 @default.
• W2020357816 hasConcept C2776694085 @default.
• W2020357816 hasConcept C2778292576 @default.
• W2020357816 hasConcept C2778822529 @default.
• W2020357816 hasConcept C2779066768 @default.
• W2020357816 hasConcept C2779984678 @default.
• W2020357816 hasConcept C2781230642 @default.
• W2020357816 hasConcept C2989005 @default.
• W2020357816 hasConcept C2993559085 @default.
• W2020357816 hasConcept C3017732841 @default.
• W2020357816 hasConcept C530470458 @default.
• W2020357816 hasConcept C535046627 @default.
• W2020357816 hasConcept C71924100 @default.
• W2020357816 hasConceptScore W2020357816C121608353 @default.
• W2020357816 hasConceptScore W2020357816C126322002 @default.
• W2020357816 hasConceptScore W2020357816C126838900 @default.
• W2020357816 hasConceptScore W2020357816C143998085 @default.
• W2020357816 hasConceptScore W2020357816C170493617 @default.
• W2020357816 hasConceptScore W2020357816C203092338 @default.
• W2020357816 hasConceptScore W2020357816C2776694085 @default.
• W2020357816 hasConceptScore W2020357816C2778292576 @default.
• W2020357816 hasConceptScore W2020357816C2778822529 @default.
• W2020357816 hasConceptScore W2020357816C2779066768 @default.
• W2020357816 hasConceptScore W2020357816C2779984678 @default.
• W2020357816 hasConceptScore W2020357816C2781230642 @default.
• W2020357816 hasConceptScore W2020357816C2989005 @default.
• W2020357816 hasConceptScore W2020357816C2993559085 @default.
• W2020357816 hasConceptScore W2020357816C3017732841 @default.
• W2020357816 hasConceptScore W2020357816C530470458 @default.
• W2020357816 hasConceptScore W2020357816C535046627 @default.
• W2020357816 hasConceptScore W2020357816C71924100 @default.
• W2020357816 hasIssue "9" @default.
• W2020357816 hasLocation W20203578161 @default.
• W2020357816 hasLocation W20203578162 @default.
• W2020357816 hasLocation W20203578163 @default.
• W2020357816 hasLocation W20203578164 @default.
• W2020357816 hasOpenAccess W2020357816 @default.

• next